Understanding H. pylori Infections
Helicobacter pylori (H. pylori), previously known as Campylobacter pylori, is a Gram-negative, flagellated, helical bacterium that colonizes the human stomach, often leading to gastrointestinal disorders such as peptic ulcers, gastritis, and occasionally gastric cancer. It is estimated that nearly half of the world’s population carries H. pylori, though not all individuals experience symptoms.1 Early and accurate detection of H. pylori is crucial for preventing complications. Noninvasive testing methods, particularly stool antigen tests, offer an effective and patient-friendly diagnostic approach.
Prevalence
H. pylori in the United States
H. pylori infection is relatively common in the United States, although its prevalence has declined over the past few decades due to improved sanitation and widespread antibiotic use. Current estimates suggest that approximately 30–40% of the U.S. population is infected with H. pylori, with higher rates observed among older adults, lower socioeconomic groups, and certain ethnic minorities.2 Infection is often acquired in childhood and persists if left untreated. The prevalence varies geographically, with higher rates seen in populations with limited access to healthcare.3
H. pylori in Alaskan Indigenous Populations
H. pylori infection rates are notably higher in certain Indigenous populations in Alaska. Studies have shown that up to 75% of Alaska Native adults and children are infected with H. pylori, significantly exceeding the national average.4 The high prevalence has been linked to factors such as crowded living conditions, limited access to clean water, and challenges in healthcare accessibility. Furthermore, Alaska Native populations experience higher rates of H. pylori-related complications, including gastric cancer, making early detection and treatment particularly critical in these communities.5
Discovery & Significance
The Fascinating Discovery of H. pylori by Barry Marshall
The discovery of H. pylori is one of the most remarkable stories in modern medicine. In the early 1980s, Australian physician Barry Marshall, along with pathologist Robin Warren, identified H. pylori as the primary cause of peptic ulcers. At the time, the prevailing belief was that ulcers were caused by stress and lifestyle factors. To prove his hypothesis, Marshall took the extraordinary step of drinking a broth containing H. pylori, subsequently developing gastritis, which he then successfully treated with antibiotics. His groundbreaking work overturned decades of medical doctrine and ultimately earned him and Warren the Nobel Prize in Physiology or Medicine in 2005.6
The Significance of Detecting H. pylori
H. pylori infection is often asymptomatic but can contribute to chronic gastritis, peptic ulcer disease, and even gastric malignancies.7 Symptoms of infection include bloating, nausea, abdominal pain, and loss of appetite. Infected individuals benefit significantly from timely diagnosis and treatment, which typically involves a combination of antibiotics and acid-suppressing medications.8
Impacts
The Enormous Healthcare Expenditures for Gastrointestinal Diseases
Gastrointestinal diseases, including those caused by H. pylori, contribute significantly to healthcare costs in the United States. In 2015, total healthcare expenditures for gastrointestinal diseases were estimated at over $135 billion, making them one of the most costly categories of healthcare spending.9 Conditions associated with H. pylori, such as peptic ulcer disease and gastric cancer, account for a substantial portion of these costs, highlighting the economic burden of undiagnosed and untreated infections. Early and accurate diagnosis using noninvasive methods can help reduce long-term healthcare costs by enabling timely treatment and preventing complications.
The Cost of Gastric Cancer in the United States
Gastric cancer, a serious potential consequence of chronic H. pylori infection, imposes a significant economic burden on the healthcare system. In the United States, the total annual cost of gastric cancer care is estimated to exceed $1.8 billion, with costs attributed to hospitalizations, treatments, and supportive care.10 The disease is often diagnosed at an advanced stage, leading to higher treatment expenses and lower survival rates. Given that H. pylori is a major risk factor for gastric cancer, early detection and eradication of the bacterium through cost-effective diagnostic methods such as stool antigen tests could play a crucial role in reducing healthcare expenditures and improving patient outcomes.
Testing Methods
Benefits of Noninvasive Testing for H. pylori
Traditionally, invasive methods such as endoscopy with biopsy have been used to diagnose H. pylori infections. While highly accurate, these procedures can be costly, uncomfortable, and carry certain risks. Noninvasive testing options, including stool antigen tests, urea breath tests, and serologic tests, provide an easier alternative with significant benefits:
- Patient Comfort and Convenience: Unlike endoscopy, noninvasive tests do not require sedation or specialized facilities, making them more accessible and less distressing for patients.11
- Cost-Effectiveness: Noninvasive tests are generally more affordable than endoscopic procedures, reducing the financial burden on healthcare systems and patients. 12 Accuracy and Reliability: Certain noninvasive tests, particularly stool antigen and urea breath tests, have high sensitivity and specificity for detecting active infections, making them reliable tools for both initial diagnosis and post-treatment confirmation.7
Why Stool Antigen Tests Are an Excellent Choice
Among noninvasive testing options, stool antigen tests are particularly advantageous due to their reliability, affordability, and practicality:
- Direct Detection of H. pylori Antigens: Unlike serologic tests, which can remain positive even after successful treatment, antigen tests detect active infections, ensuring accurate diagnosis.13
- Useful for Test-of-Cure: Stool antigen tests are recommended for confirming eradication of H. pylori following treatment, as they effectively identify ongoing infections.11
- Noninvasive and Easy to Perform: Collecting a stool sample is a simple process that can be done at home, making it more comfortable for patients than breath tests, which require specialized equipment.
- Effective in Different Age Groups: Stool antigen tests have been shown to be particularly useful for diagnosing H. pylori in children, who may have difficulty complying with breath tests.14
QwikID™ H. pylori Rapid Antigen Test is an FDA-cleared in vitro diagnostic lateral flow assay for the qualitative detection of H. pylori antigen in human stool specimens.
Features:
- 10-minute results for faster treatment decisions.
- Easy-to-use design suitable for busy healthcare environments.
- No additional tools or components needed.
- FDA-cleared for reliable and accurate detection.
- Room temperature storage with a long shelf life.
- Free sample kits available for new users.
- Affordable pricing designed for labs of all sizes.
- Saves precious bench space since no additional equipment is needed.
Meet the author
CLINICAL PRODUCT MANAGER at HARDY DIAGNOSTICS
Megan Roesner, B.A. Journalism and Mass Communications
Megan is a seasoned writer and marketing professional who comes from a background in television journalism, followed by fifteen years leading mulitple hospital marketing and communications teams with the largest not-for-profit health system in the U.S. Megan has won numerous tv, writing and marketing awards and is a member of a number of professional public relations and marketing associations. Her passion for continuous professional challenges and life-long learning led her to Hardy Diagnostics. Megan is proud to work amongst a wonderful marketing team surrounded by experienced microbiologists and scientists who constantly push for the latest and greatest products to help diagnose and detect disease. In her current role, Megan is in charge of product development and marketing Hardy's clinical category which encompasses hospitals and health systems, clinics and research institutions, higher education and veterinary diagnostics. In her free time, Megan enjoys being a mom to her two very active boys, cats, a dog, a very old goldfish and 24 chickens.
References
1. Suerbaum, S., & Michetti, P. (2002). Helicobacter pylori infection. New England Journal of Medicine, 347(15), 1175-1186.
2. Eusebi, L. H., Zagari, R. M., & Bazzoli, F. (2014). Epidemiology of Helicobacter pylori infection. Helicobacter, 19(s1), 1-5.
3. Perez-Perez, G. I., et al. (2002). Role of Helicobacter pylori infection in the development of gastric malignancies. Clinical Microbiology Reviews, 15(3), 544-560.
4. Bruce, M. G., Maaroos, H. I., & Taylor, D. E. (2005). Helicobacter pylori in Alaska Native populations: A review of epidemiology and disease. Helicobacter, 10(4), 253-267.
5. Gessner, B. D., Bruce, M. G., & Parkinson, A. J. (2011). The epidemiology and control of Helicobacter pylori infection in Alaska Native peoples. Epidemiology and Infection, 139(4), 528-541.
6. Marshall, B. J., & Warren, J. R. (1984). Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. The Lancet, 323(8390), 1311-1315.
7. Malfertheiner, P., Megraud, F., O'Morain, C. A., Gisbert, J. P., Kuipers, E. J., Axon, A. T., ... & Sugano, K. (2017). Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut, 66(1), 6-30.
8. Chey, W. D., Leontiadis, G. I., Howden, C. W., & Moss, S. F. (2017). ACG clinical guideline: Treatment of Helicobacter pylori infection. The American Journal of Gastroenterology, 112(2), 212-239.
9. Peery, A. F., et al. (2019). Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2018. Gastroenterology, 156(1), 254-272.
10. Medeiros, M. S., et al. (2020). The economic burden of gastric cancer in the United States. Gastrointestinal Cancers Review, 15(3), 189-201.
11. Gisbert, J. P., & Pajares, J. M. (2004). Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter, 9(4), 347-368.
12. Hunt, R. H., Xiao, S. D., Megraud, F., Leon-Barua, R., Bazzoli, F., Van der Merwe, S., ... & Tytgat, G. N. (2015). Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guidelines.
13. Vaira, D., Malfertheiner, P., Megraud, F., Axon, A. T., Deltenre, M., Hirschl, A. M., ... & Tytgat, G. N. (2002). Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. The Lancet, 359(9317), 447-448.
14. Mégraud, F., Lehours, P., & Vale, F. F. (2016). The history of Helicobacter pylori: from first culture to genome sequence. World Journal of Gastroenterology, 22(6), 1784-1804.
